ARHGAP26 and cancer: In the present study, 26 of the 254 gastric cancers examined in our cohort had CLDN18-ARHGAP26/6 fusions, and 22 of the 26 gastric cancers with the fusions were DGCs (22 cancers of 172 DGCs, 12.8%).